GTCM
ZNTL icon

Gyon Technologies Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Gyon Technologies Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,905
Closed -$864K – 441
2022
Q4 		$864K Buy
42,905
+29,408
+218% +$632K 0.32% 100
2022
Q3 		$292K Sell
13,497
-5,135
-28% -$140K 0.09% 279
2022
Q2 		$524K Buy
+18,632
New +$494K 0.15% 163

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gyon Technologies Capital Management's ZNTL Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2023, closing a stake of 42,905 shares — an estimated $864K sold.

Gyon Technologies Capital Management first reported a position in ZNTL in Q2 2022 and held it in 3 quarters. The position peaked at $864K in Q4 2022. 110 funds tracked by Wall St. Rank hold ZNTL as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 42,905 Zentalis Pharmaceuticals shares in Q1 2023, an estimated $864K.
  • Gyon Technologies Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Gyon Technologies Capital Management's Zentalis Pharmaceuticals position peaked at $864K in Q4 2022.
  • 110 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.